⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MYGN News
Myriad Genetics Inc
Alamar Biosciences gibt Abschluss der überzeichneten Wandelanleihe-Finanzierung und Erweiterung des Führungsteams bekannt USA - Deutsch USA - Français USA - English APAC - English USA - English USA - čeština
prnewswire.com
AMGN
ILMN
VRTX
RIVN
TROW
PRGS
ALNY
REGN
GILD
BMY
MRK
ABBV
AZN
SNY
NVS
XRAY
EVTC
MYGN
RVTY
VTRS
BIIB
MDLZ
PFE
SNDX
EXAS
CRSP
NTRA
ON
IDXX
MDT
SYK
ISRG
DXCM
COO
AMZN
GOOG
MSFT
NVDA
IBM
INTC
QCOM
AMD
MU
ADBE
CRM
ORCL
SAP
CSCO
ACN
HPQ
DELL
MSCI
FIS
PAYX
ADP
BBBY
ROST
TJX
MCHP
NXPI
SNPS
CDNS
WDC
STX
KLAC
LRCX
AMAT
CTAS
PAYC
NOW
DDOG
ZS
PANW
FTNT
SNOW
PYPL
V
MA
AXP
BAC
JPM
WFC
C
GS
MS
SCHW
ELAN
ZTS
ALGN
XOM
CVX
KO
PEP
MCD
DIS
CMCSA
VZ
T
NFLX
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team USA - English APAC - English USA - English
prnewswire.com
AMGN
VRTX
ILMN
RVTY
MYGN
TROW
Myriad Genetics to Present at 44th Annual J.P. Morgan Healthcare Conference
globenewswire.com
MYGN
Myriad Genetics to Present 8 Abstracts about MRD and Other Studies at 2025 San Antonio Breast Cancer Symposium
globenewswire.com
MYGN
Companion Diagnostics Market Research 2025: $21+ Bn Opportunities, Growth Drivers, Industry Trend Analysis, and Forecasts 2024-2034
globenewswire.com
PFE
MRK
AZN
TMO
ABT
AMGN
JNJ
BMY
LLY
MYGN
GRDX
BIIB
BDX
4D Path’s Physics-Inspired QPOR™ Platform Predicts Neoadjuvant Chemotherapy Response from Routine Biopsy Images in Early-Stage Triple-Negative Breast Cancer from Phase II TBCRC-030 Trial
globenewswire.com
MYGN
Consumer DNA (Genetic) Testing Market Forecasts Report 2025-2030: Asia-Pacific Shows High Growth Potential, Alongside Europe and North America
globenewswire.com
ANCS
ME
DGX
LH
MYGN
CLBR
GENE
Clairity, Myriad Genetics, and MagView Launch the First Integrated AI and Genetic Risk Platform for Personalized Breast Health
globenewswire.com
MYGN
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences
globenewswire.com
MYGN
Myriad Genetics Adds 15 Clinically Actionable Genes to MyRisk® Hereditary Cancer Test to Support Evolving Clinical Needs
globenewswire.com
MYGN